Current advancements and potential strategies in the development of MERS-CoV vaccines
about
Critically ill patients with Middle East respiratory syndrome coronavirus infectionMiddle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak controlReceptor-binding domain-based subunit vaccines against MERS-CoVMiddle East respiratory syndrome: obstacles and prospects for vaccine developmentMERS-CoV spike protein: a key target for antivirals.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases.Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like diseaseA Computational Approach for Predicting Role of Human MicroRNAs in MERS-CoV Genome.Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseasesDevelopment of animal models against emerging coronaviruses: From SARS to MERS coronavirusDevelopment of Monoclonal Antibody and Diagnostic Test for Middle East Respiratory Syndrome Coronavirus Using Cell-Free Synthesized Nucleocapsid Antigen.Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Computational modeling of the bat HKU4 coronavirus 3CL(pro) inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus.Vaccines for the prevention against the threat of MERS-CoV.Recent advances in the production of recombinant subunit vaccines in Pichia pastoris.Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8+ T Cell Epitopes and Host MHC.A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.Biochemical Characterization of Middle East Respiratory Syndrome Coronavirus Helicase.Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.
P2860
Q26764948-43F790EC-17F9-4989-915B-DAE80F9B4212Q26796501-B2221DAB-5DF8-40CA-AB59-BFA07C682ED2Q26851979-F9449244-4B17-4B08-94F4-0D75BE5435F2Q27013314-77C002AE-B3DA-46D2-A4C3-75ED08932F01Q30240139-9697725F-8703-4B29-9D42-D5CE4CC05C7FQ30371303-49FC239E-C6C1-489E-8ABE-79CC401E59E7Q30382230-DF209A22-7D59-4704-9196-1D7D70F6C90CQ30399700-2881F820-C727-4085-B6EA-FCC46B201A35Q30400066-C6EE14F4-ABA7-4963-96A3-01CC8DF72EB0Q34324907-3698BDC6-2BFB-4570-A2F7-4519AB757FDAQ34468689-A6B1EA43-1B45-44EE-91B3-0EE6ABFDCF1EQ34813357-0619A936-6200-48F4-AC96-7D87D168A1FCQ35887626-1F987595-E0DD-463C-B366-668631E9D50FQ36550981-5F775F65-D49C-4BFE-9898-756980FB5619Q36691163-4D5FB44E-B3F3-432D-8BE4-E0C8A1FB0075Q36814211-FBE59C80-BBC7-4E95-A6F1-06810A1B56E2Q37320159-3D7EC4A2-99E5-4C5D-AE03-9C341779E8AFQ37434385-78609329-E75F-4FED-8C53-A1AE07026575Q37512915-94E2C056-D466-4179-B92C-B13F187B2BE0Q38388047-47C3F935-F046-49D4-A6BD-CAA3DC520929Q38461061-4C93E2A9-5C6A-4B1B-A0C4-5207637FB8B6Q38728233-CB5E9664-D0C8-4BE0-B2A4-141EBC4A99A8Q38778044-E404F056-42B2-491D-BE32-5B8A5E21E3ADQ38849581-DB35441C-1D94-4CD0-B6A7-38D880B54C07Q40428932-6E135E8F-5552-4293-815B-30E2E11AD2B1Q40503787-53E9FB15-12ED-4420-A280-CC7877033B25Q40580677-65BFE7FE-7EE2-4ACC-A45F-E4CB9675D5BEQ47607374-D26C4CFF-06B8-499D-BB20-93E59352334D
P2860
Current advancements and potential strategies in the development of MERS-CoV vaccines
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Current advancements and potential strategies in the development of MERS-CoV vaccines
@ast
Current advancements and potential strategies in the development of MERS-CoV vaccines
@en
Current advancements and potential strategies in the development of MERS-CoV vaccines
@nl
type
label
Current advancements and potential strategies in the development of MERS-CoV vaccines
@ast
Current advancements and potential strategies in the development of MERS-CoV vaccines
@en
Current advancements and potential strategies in the development of MERS-CoV vaccines
@nl
prefLabel
Current advancements and potential strategies in the development of MERS-CoV vaccines
@ast
Current advancements and potential strategies in the development of MERS-CoV vaccines
@en
Current advancements and potential strategies in the development of MERS-CoV vaccines
@nl
P2860
P3181
P1476
Current advancements and potential strategies in the development of MERS-CoV vaccines
@en
P2093
Naru Zhang
P2860
P304
P3181
P356
10.1586/14760584.2014.912134
P407
P577
2014-06-01T00:00:00Z